Lisata Therapeutics Inc. (LSTA NASDAQ) stock market data APIs
$5.0169
0(0%)
as of March 16, 2026
Try our APIs with
free plan!
Lisata Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Prev. Close
5.0169
Open
4.9945
High
5.0717
Low
4.9709
52 wk Range
1.81-5.07
Market Cap
45 523 K
Shares Outstanding
9 032 K
Revenue
170 K
EPS
0
Beta
1.274
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lisata Therapeutics Inc. data using free add-ons & libraries
Get Lisata Therapeutics Inc. Fundamental Data
Lisata Therapeutics Inc. Fundamental data includes:
- Net Revenue: 170 K
- EBITDA: -18 063 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: -0.625
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lisata Therapeutics Inc. News
New
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Sharehold...
Lisata Therapeutics to be acquired by Kuva Labs
Lisata Therapeutics to be acquired by Kuva Labs Proactive uses images sourced from Shutterstock Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing the...
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously...
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
Get Lisata Therapeutics Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
